CBD for dogs and cats is a category where the marketing got ahead of the science by about a decade, and the science is finally catching up. As of April 2026, an estimated 7.3% of US companion dogs receive a CBD or hemp product — about 18% in dogs with dementia, 12.5% in dogs with osteoarthritis, and 10% in dogs with cancer, per the Dog Aging Project's 47,355-dog observational analysis published late 2025. That is a meaningful slice of households, on a product that is not FDA-approved for animal use. What follows is what the published veterinary literature shows as of this spring, written for owners who want the evidence rather than the slogans.
A note on terminology before we start. CBD (cannabidiol) is one of more than 100 cannabinoids in the cannabis plant; hemp is the cultivar of cannabis with less than 0.3% THC by dry weight. "Hemp oil" on a pet store shelf can mean either a CBD-containing extract or simply hemp seed oil (a culinary fat with no meaningful cannabinoid content). They are not interchangeable. If the label does not state cannabinoid potency in milligrams, it is the seed oil.
How CBD Acts in the Mammalian Body
CBD interacts with the endocannabinoid system, a receptor and lipid-signaling network present in all mammals studied, including dogs and cats. Two principal receptors — CB1 (concentrated in the central nervous system) and CB2 (peripheral, immune, gastrointestinal) — modulate inflammation, pain perception, anxiety responses, appetite, and sleep. CBD is a weak partial agonist at these receptors and acts more strongly through indirect pathways: it inhibits the breakdown of anandamide (the body's own cannabinoid), interacts with serotonin 5-HT1A receptors at higher doses, and modulates TRPV1 (vanilloid) channels involved in pain signaling.
Unlike THC, CBD is not psychoactive and does not produce intoxication. The clinical interest in CBD for pets rests on this combination: a measurable mechanism, a tolerable safety profile in published trials, and a category of conditions (chronic pain, atopic dermatitis, refractory seizures, situational anxiety) where conventional treatments are imperfect and adjunct options are welcome.
That is the mechanistic case. The evidence case is more uneven, which is why an honest version of this article needs an evidence tier.
What the Research Actually Shows: An Evidence Tier
Not all "CBD studies" are the same kind of evidence. A randomized controlled trial in 80 dogs is not the same level of confidence as a single case report. Below is how I read the canine and feline CBD literature as of April 2026:
| Use case | Evidence level | Key citations |
|---|---|---|
| Canine osteoarthritis pain | RCT-supported | Cornell 2018 RCT: >80% of arthritic dogs showed decreased pain at 2 mg/kg PO every 12 hours (Cornell Riney Canine Health Center). |
| Canine post-surgical (TPLO) pain — adjunct | RCT-supported (recent, single trial) | Frontiers in Veterinary Science 2025: 48 dogs, 20:1 CBD:THC extract, double-blind placebo control. The strongest design yet for surgical pain. |
| Canine refractory epilepsy — adjunct | RCT-supported (small) | Colorado State pilot work; consistent with the FDA-approved human drug Epidiolex precedent. CBD for epilepsy in animals is always adjunct to standard anti-seizure therapy, never a replacement. |
| Canine atopic dermatitis | RCT-supported (single trial) | CannPal trial: 65% of CBD-treated dogs had ≥50% reduction in itching/chewing scores. |
| Situational/stress anxiety in dogs | Mixed (controlled + observational) | Cornell observational: 83% of dogs showed decreased stress/anxiety behaviors. ScienceDirect 2024: both oil and gel formulations significantly lowered post-stress cortisol vs. placebo in shelter dogs. |
| Canine cognitive dysfunction (dementia) | Observational only | Dog Aging Project 2025 — dogs on long-term CBD trended toward less aggression over time; behavioral signal, not a controlled trial. |
| Feline osteoarthritis | Field study (single) | Mulder et al., J Feline Med Surg 2025: CBD/CBDA-rich hemp paste in cats with OA pain. |
| Cancer adjunct, IBD, generalized anxiety in cats | Mechanistic only | Receptor-level rationale; no published controlled outcome trials. |
| Wellness/preventive use in healthy pets | Anecdotal | No controlled evidence of benefit in animals without a target condition. |
The honest summary: the evidence for canine osteoarthritis pain and for refractory epilepsy as an adjunct is the strongest. Surgical pain has one well-designed trial. Anxiety has consistent observational signal but seasonal complications (firework- and thunderstorm-driven anxiety is the highest-volume search query and the hardest condition to study because exposure is unpredictable). The wellness-blog framing of CBD as a daily supplement for healthy pets has essentially no published evidence behind it.
Related Article: Pet Care through Different Lenses: A Neurodiversity Discussion
CBD for Dog Anxiety: What the Trials Show
Anxiety is the most-searched application of pet CBD and one of the most seasonally driven — query volume for "cbd for dog anxiety" peaks every July around fireworks. The published evidence is encouraging but still thinner than the marketing suggests. The Cornell-led observational work reports 83% of dogs showed a decrease in stress- or anxiety-related behaviors during CBD use. The 2024 ScienceDirect shelter-dog study (a controlled comparison of oil and gel formulations against placebo) showed a statistically significant reduction in post-stress cortisol on both formulations.
What is missing from the literature is a definitive RCT in the situational-anxiety setting that owners actually care about — separation anxiety, noise phobia, vet-visit stress. Until those exist, CBD for canine anxiety is reasonably described as: plausible mechanism, encouraging early data, no confirmed superiority over established options like fluoxetine, gabapentin, trazodone, or a behavior-modification plan with a board-certified behaviorist (DACVB). It is a candidate adjunct, not a first-line replacement.
If you and your vet decide to try CBD for anxiety, the published research dose range (see the dosing section below) is the place to start. Pair it with environmental management — counterconditioning, predictable routines, white noise during fireworks — and give it a fair trial of several weeks before judging effect.
CBD for Dog Pain and Arthritis: The Strongest Evidence
This is where the literature is most mature. The 2018 Cornell osteoarthritis RCT remains the most widely cited canine CBD study: at 2 mg/kg orally every 12 hours, more than 80% of dogs showed decreased pain and increased activity, with no clinically significant adverse events at four weeks. The 2025 Frontiers post-TPLO surgical pain trial — 48 dogs, double-blind, placebo-controlled, with a 20:1 CBD:THC formulation — extends the evidence into the acute surgical setting.
Two practical points about pain use. First, CBD is an adjunct, not a replacement for standard analgesics. Most arthritic dogs in the published trials were also receiving a non-steroidal anti-inflammatory drug or another pain medication, and the CBD effect is on top of, not instead of, the standard of care. Second, as discussed below, CBD inhibits the liver enzymes that metabolize many pain medications — so adding it to an existing regimen is a pharmacologic decision, not a supplement decision, and your vet needs to know.
Is CBD Safe for Dogs? Side Effects and Drug Interactions
Published safety data through 2025 supports CBD as broadly safe in dogs at 5 mg/kg/day for at least 90 days (NASC long-term safety data) and at up to 10 mg/kg/day for 36 weeks (Cornell safety review). The most consistently observed effect across studies is a reversible elevation in serum alkaline phosphatase (ALP), driven by hepatic enzyme upregulation — a lab abnormality, not in itself a clinical problem in healthy dogs, but worth monitoring with periodic chemistry panels in long-term use. Other commonly reported effects: sedation, mild gastrointestinal upset, and increased appetite.
The single most under-discussed safety topic in consumer pet-CBD content is drug interactions. CBD inhibits the cytochrome P450 enzymes that metabolize many pet medications. The 2024 Court et al. paper in Journal of Veterinary Pharmacology and Therapeutics confirmed in vitro that canine CYP1A2 and CYP2C21 — the two principal hepatic P450 enzymes in dogs — are substantially inhibited by CBD. The clinical translation of that mechanism varies by drug. The 2022 controlled study in American Journal of Veterinary Research found no clinically significant pharmacokinetic interaction between CBD and phenobarbital at typical doses, although ALP monitoring was still recommended. Other combinations have not been formally tested in dogs and require clinical caution.
A practical drug-interaction overview:
| Co-medication | Interaction risk | Practical guidance |
|---|---|---|
| Phenobarbital | Mechanistic concern; clinical RCT showed no significant PK interaction at standard doses | Monitor liver enzymes (ALP, ALT) more frequently; coordinate with neurologist |
| NSAIDs (carprofen, meloxicam, robenacoxib, grapiprant) | Plausible CYP-mediated interaction; not formally studied in dogs | Watch for additive GI / hepatic / renal effects; do not combine without vet input |
| Azole antifungals (fluconazole, ketoconazole) | Both inhibit P450s — combined inhibition possible | Discuss alternatives or close monitoring |
| Tramadol, opioids | CYP2D-pathway concerns by analogy to humans; not formally studied in dogs | Approach with caution; coordinate with vet |
| Cyclosporine, tacrolimus (immunosuppressants) | Narrow therapeutic index drugs; CBD interaction plausible | Avoid concurrent use without specialist supervision |
| SSRIs / TCAs (fluoxetine, clomipramine) | Theoretical interaction via CYP and 5-HT1A receptor effects | Discuss with vet behaviorist |
The rule I give clients: tell your veterinarian every supplement and every medication your animal takes, and tell them before you add CBD, not after.
How Much CBD Should I Give My Dog? A Dosing Framework
There is no FDA-established veterinary CBD dose. What follows are the dose ranges used in published clinical research, presented as ranges and not as prescriptions. Your individual dog's dose depends on weight, condition, concurrent medications, and product potency, and only your veterinarian can responsibly individualize it.
| Use case | Published research dose | Source |
|---|---|---|
| Canine osteoarthritis pain | 2 mg/kg every 12 hours (4 mg/kg/day) | Cornell 2018 RCT |
| General supplementation, long-term safety reference | Up to 5 mg/kg/day for 90 days | NASC long-term safety data |
| Upper-bound safety ceiling studied | Up to 10 mg/kg/day for 36 weeks | Cornell safety review |
| Healthy cats — tolerated maintenance | 4 mg/kg/day for 4 weeks | Frontiers 2023 |
Practical calculation for a 30 kg Labrador with osteoarthritis: at the Cornell 2 mg/kg BID dose, that is 60 mg twice daily, or 120 mg/day. From a tincture with 30 mg/mL potency, that is 2 mL twice daily — assuming the label potency is accurate, which is not a given (see the COA section below).
A note on state law. As of 2026, the only US state where veterinarians have full statutory authority to recommend, administer, and dose CBD/hemp products under 0.3% THC is Nevada (effective October 1, 2023, under NRS Chapter 638). In California, vets may discuss CBD with clients but cannot recommend specific products or doses (SB 627, 2018). Several other states have intermediate frameworks; Maryland's SB 54 / HB 452 in 2026 would make it the fifth state to formalize. If your veterinarian is reluctant to give you a specific number, this is often the reason — and it is not negligence on their part. The most current 50-state tracker is maintained by Lolahemp.
CBD for Cats: What's Different
Cats are not small dogs at the bowl, and they are not small dogs in pharmacokinetics either. A 2024 Frontiers study found that cats absorb CBD less efficiently than dogs and eliminate it slightly more slowly: half-life of about 1.5 hours in cats vs. ~1 hour in dogs from a single dose. Cats also have well-documented sensitivity to THC — markedly more so than dogs — which is why the 0.3% THC ceiling on hemp-derived products and the use of CBD isolate formulations (zero THC) are particularly important in this species.
The encouraging feline data: a 2023 Frontiers safety study showed healthy cats tolerated 4 mg/kg/day for four weeks without clinically significant changes in CBC or serum chemistry. The 2025 Mulder field trial in Journal of Feline Medicine and Surgery evaluated a CBD/CBDA-rich hemp paste in cats with osteoarthritic pain and reported tolerability and signal of efficacy — preliminary, but one of the few feline efficacy studies in the literature.
What the feline literature does not yet support: CBD as a generalized anxiolytic in cats, CBD for feline IBD, and CBD as a cancer adjunct. Each has mechanistic plausibility and zero published controlled trials. If you and a feline-experienced veterinarian decide to try CBD for an off-label feline indication, the 4 mg/kg/day tolerated maintenance dose from the 2023 study is a reasonable starting reference, with close clinical and lab monitoring.
How to Read a Certificate of Analysis
The pet CBD market is unregulated for medical claims and inconsistently regulated for product quality. A 2020 Cornell evaluation of 29 pet CBD products found heavy-metal contamination and substantial labeling inaccuracies in a meaningful fraction of the sample. The single most useful consumer-protection skill is reading a Certificate of Analysis (COA), the third-party lab report that quality manufacturers post per lot.
A 90-second COA check:
- Cannabinoid potency match-to-label. The mg/mL of CBD on the COA should match the bottle within ±10%. If the COA reports half what the label claims, the product is mislabeled.
- THC under 0.3%. Federal hemp definition. For cats, prefer products that are CBD isolate (zero THC).
- Heavy metals. Arsenic, cadmium, lead, mercury — all should be reported "non-detectable" or below USP limits. The hemp plant is a phytoremediator: it pulls heavy metals out of soil.
- Microbial / yeast / mold. Should be below specification. A failing microbial result is a red flag for contaminated raw material.
- Residual solvents and pesticides. Should be below detection limits. Solvent residues are a manufacturing-process indicator.
The COA should also be lot-specific, dated within the last 12 months, and from an ISO 17025-accredited laboratory. If a brand cannot or will not produce a current COA on request, that is the information you need. The NASC Quality Seal is a reasonable secondary signal — it indicates third-party audit and adverse-event reporting compliance, though it does not certify clinical efficacy.
FDA Status, State Laws, and What's Changing in 2025–2026
A clear-eyed regulatory snapshot as of April 2026:
- No cannabis-derived product is FDA-approved for animal use. The only FDA-approved cannabis-derived drug remains Epidiolex, for refractory pediatric epilepsy in humans.
- The FDA opened a formal docket on veterinary cannabis on January 16, 2025 — the Federal Register notice requested information on safety, efficacy, manufacturing, and clinical use ahead of potential rulemaking. Comments closed in spring 2025. This is the first time the FDA has signaled a structured path toward eventual veterinary CBD regulation.
- On April 7, 2025, the FDA issued warning letters to three pet CBD companies — Bailey's Wellness, Holista, and House of Alchemy / Hamet & Love — for marketing unapproved CBD products with disease claims. The pattern is consistent: the FDA does not police sale of pet CBD broadly, but it does police medical claims. Brands advertising "treats arthritis" or "cures anxiety" are the legal targets.
- The AVMA released its updated Cannabis in Veterinary Medicine report in March 2026 — the first major refresh of the AVMA position document since 2020. It acknowledges therapeutic promise for epilepsy, osteoarthritis pain, and inflammation while reiterating that scientific evidence in animals remains limited and that no products are federally approved.
- State law on veterinary recommendation varies materially. Nevada is the only state where vets have full authority to recommend, administer, and dose hemp products under 0.3% THC. California vets may discuss CBD but not recommend specific products or doses. Maryland (SB 54 / HB 452, pending 2026), Michigan, New York, and Utah have intermediate frameworks. Where you live affects whose advice you can get.
Translation for owners: the regulatory environment is moving, slowly, toward formalization. In the meantime, treat any pet CBD product as an unapproved supplement — useful for some indications when chosen carefully, not a substitute for diagnosed veterinary care.
When to Call Your Vet: THC Toxicosis Red Flags
The actual emergency presentation in pet cannabis exposure is THC toxicosis, almost always from accidental ingestion of a human cannabis product (edibles, flower, resin) rather than from a properly dosed, low-THC pet CBD product. With cannabis legalization expanding state by state, ER visits for pet cannabis toxicosis have risen sharply over the past decade — this is now a routine emergency-department conversation, not a rare one.
Call your veterinarian or a poison helpline immediately if you observe any of:
- Ataxia (uncoordinated gait, swaying, falling)
- Urinary incontinence in an animal that is normally house-trained — a classic and surprisingly specific sign
- Bradycardia (slow heart rate) or, less commonly, tachycardia
- Hyperesthesia (exaggerated startle response to sound or touch)
- Dilated pupils with a fixed, glazed look
- Profound lethargy or, in severe cases, stupor
Phone numbers worth saving:
- ASPCA Animal Poison Control Center — 888-426-4435 (a fee applies, but they coordinate directly with your vet)
- Pet Poison Helpline — 855-764-7661
Do not induce vomiting at home unless instructed by a veterinarian. THC toxicosis is rarely fatal with supportive care (IV fluids, anti-nausea, monitoring), but it requires veterinary evaluation, especially in cats and small dogs and in cases involving chocolate or other co-ingredients common to human edibles.
Related Article: The Rise of Exotic Pets: Care Tips for Unconventional Companions
A Brief Closing Note
CBD for pets is the kind of topic where the honest answer changes — slowly — every year. The literature in 2026 supports a measured optimism for canine osteoarthritis pain, a narrower but real role for refractory epilepsy as an adjunct, and a growing observational base for anxiety and dementia behavioral signs. It does not yet support the wellness-supplement framing for healthy animals, and it does not absolve owners or their veterinarians of the safety conversations around drug interactions, product quality, and species differences in cats.
The framework above is what the published peer-reviewed evidence and the major veterinary organizations — AVMA, AAHA, ACVIM — broadly support as of April 2026. The places where the evidence is genuinely soft are places where I would rather say so than dress them up. Individual decisions — whether your dog is a candidate, what dose is appropriate, which product to trust, how to monitor — belong with your own veterinarian, who has the exam-room context and the medication record I do not.
Last reviewed 2026-04-29 by Dr. Maren Holbrook, DVM.
Frequently Asked Questions
Published safety data through 2025 supports CBD as broadly safe in dogs at up to 5 mg/kg/day for at least 90 days (NASC long-term safety data) and at up to 10 mg/kg/day for 36 weeks (Cornell safety review). The most consistently observed effect is a reversible elevation in alkaline phosphatase (ALP) from hepatic enzyme upregulation. CBD is not FDA-approved for animals, and any product should be discussed with your veterinarian, especially if your dog takes other medications.
There is no FDA-established veterinary dose. Published clinical trials have used 2 mg/kg every 12 hours (Cornell osteoarthritis study) and up to 5 mg/kg/day for general supplementation (NASC long-term safety). Your individual dog's dose depends on weight, condition, concurrent medications, and product potency — only your veterinarian can responsibly individualize it. Where state law restricts vet recommendations (only Nevada has full authority as of 2026), ask about your state's specific framework.
The most commonly reported effects are sedation, mild gastrointestinal upset, and increased appetite. Lab monitoring frequently shows reversible elevation in alkaline phosphatase (ALP). At very high or contaminated doses, signs of THC toxicosis (ataxia, urinary incontinence, slow heart rate, dilated pupils, hyperesthesia) require immediate veterinary care.
Yes. CBD inhibits canine cytochrome P450 enzymes (CYP1A2, CYP2C21) that metabolize many pet drugs (Court et al., 2024). A 2022 controlled study found no clinically significant pharmacokinetic interaction between CBD and phenobarbital at typical doses, but liver-enzyme monitoring is still advised. Be cautious with NSAIDs, antifungals (fluconazole, ketoconazole), immunosuppressants, and other liver-metabolized drugs — always tell your vet what your dog is taking before starting CBD.
Cats absorb CBD less efficiently and eliminate it slightly more slowly than dogs (half-life ~1.5 hours vs. ~1 hour). A 2023 Frontiers study showed healthy cats tolerated 4 mg/kg daily for 4 weeks without clinically significant CBC or chemistry changes. Cats are notably more sensitive to THC, so products must be high quality, third-party tested, and below 0.3% THC — preferably CBD isolate. Discuss with a feline-experienced veterinarian before starting.
Hemp-derived CBD (under 0.3% THC) is legal at the federal level following the 2018 Farm Bill, but as of April 2026 the FDA has not approved any cannabis-derived product for animal use. Whether your veterinarian can formally recommend, dose, or sell CBD depends on your state — Nevada permits it fully (since October 2023); California and several others allow discussion only; Maryland's SB 54 / HB 452 is pending in 2026. The FDA opened a formal docket on veterinary cannabis in January 2025.
Peak blood levels in dogs occur about 1–2 hours after an oral dose, with a half-life near 1 hour for single doses. For acute or situational anxiety, owners typically observe effects within 30–90 minutes. For chronic conditions like osteoarthritis, published trials evaluated outcomes at 4–12 weeks — give a consistent dose for several weeks before judging effectiveness.
